Genentech initiates Phase II trial of RG6434 in early symptomatic Alzheimer's disease
Genentech and Roche are initiating the Phase II TARBELA-AD trial to evaluate oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease.
1. Trial and research updates
The TARBELA-AD trial will evaluate oral RG6434, which targets neuroinflammation. Trial designs and new research are scheduled for presentation at the CTAD Congress in Boston, November 16-19, 2026.
2. Trontinemab and diagnostics
Updated Phase Ib/IIa data for trontinemab show rapid amyloid removal and changes in key biomarkers. Phase III PrevenTRON has begun enrolling cognitively unimpaired participants with Alzheimer's biomarkers at high risk of clinical decline. Presentations will also examine clinical performance and economic implications of Elecsys pTau217 and pTau181 blood tests across care settings.
